We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App





Diatron Introduces New Aquila 5Dretic 5-Part Differential Hematology Analyzer

By LabMedica International staff writers
Posted on 20 Nov 2019
Print article
Image: Diatron Aquila 5Dretics (Photo courtesy of Diatron)
Image: Diatron Aquila 5Dretics (Photo courtesy of Diatron)
Diatron (Budapest, Hungary) introduced its new high throughput, 5-part differential hematology analyzer with continuous loading autoloader for the first time at the MEDICA 2019 Trade Fair held in Düsseldorf, Germany from 18-21st November. The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.

Diatron, a global provider of hematology and clinical chemistry analyzers, also showcased its P500 flagship clinical chemistry analyzer, and the Diatron KleeYa, an open, flexible CLIA platform, and demonstrated the Aquila 3-part diff hematology analyzer from its current hematology product portfolio.

The Diatron Aquila 5Dretics is the smallest and most compact cap piercing 5-part differential hematology analyzer with a maximum throughput of 80 tests per hour. It has a low reagent consumption (<30 ml), requires a small sample volume (40 ul) and has a continuous loading autoloader, making the walk away system convenient for all customers. It uses only two reagents as it is a fully optical system, resulting in low reagent consumption and making it more cost-effective. The Diatron Aquila 5Dretics requires little bench space (32 cm W x 30 cm D x 37 cm H without autoloader) and features a large touch screen, an intuitive user interface and a protected reagent pack system with unique connection

At the 2019 edition of MEDICA, Diatron also showcased its P500 flagship clinical chemistry analyzer. The P500 is an ergonomically designed, user-friendly system that offers a high level of automation and delivers assured result quality. The cost-effective, walkaway system is intended for medium throughput usage, providing results for 215 tests per hour on a typical sample mix. Also showcased at the event was Diatron KleeYa, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.

Additionally, Diatron demonstrated the Aquila 3-part diff hematology analyzer which offers a throughput of 60 tests per hour, requires a sample size of only 10µl, and consumes less than 10ml of reagent per test. It is equipped with an onboard reagent pack sufficient for approximately 200 measurements and includes a touchscreen, intuitive user interface, optional backup battery pack, and extended connectivity options.

Related Links:
Diatron

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.